Drug Price Trends for BUTALBITAL-ACETAMINOPHEN-CAFFEINE

Average Pharmacy Cost for BUTALBITAL-ACETAMINOPHEN-CAFFEINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE	11534-0187-01	0.43697	EACH	2025-05-21
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE	16714-0170-01	0.43697	EACH	2025-05-21
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE	00591-2640-05	0.43697	EACH	2025-05-21
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE	42195-0955-10	0.43697	EACH	2025-05-21
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE	00527-4095-37	0.43697	EACH	2025-05-21
BUTALBITAL-ACETAMINOPHEN-CAFFEINE-CODEINE 50-325-40-30 MG CP	51991-0073-01	0.85064	EACH	2025-05-21

Market Analysis and Price Projections for Butalbital-Acetaminophen-Caffeine

Introduction

The combination of butalbital, acetaminophen, and caffeine is a widely prescribed medication, particularly for the treatment of tension headaches. This article delves into the market analysis, price projections, and other key aspects of this drug combination.

Medical Uses and Indications

Butalbital-acetaminophen-caffeine is primarily indicated for the treatment of tension headaches. The synergistic effect of its components—acetaminophen providing analgesic and antipyretic properties, butalbital acting as a muscle relaxant and sedative, and caffeine enhancing pain-relieving effects—makes it an effective option for managing headache pain[1][4].

Market Size and Growth

The global acetaminophen market, which includes combinations like butalbital-acetaminophen-caffeine, was valued at USD 9.8 billion in 2022 and is projected to grow at a CAGR of 4.2% to reach USD 15.2 billion by 2033. This growth is driven by increasing chronic illnesses, such as cancer and chronic obstructive pulmonary disease (COPD), and the need for effective pain management[3].

Regional Market Analysis

• United States: The combination of butalbital-acetaminophen-caffeine was the 248th most commonly prescribed medication in the U.S. in 2022, with over 1 million prescriptions. The U.S. market is significant due to the high prevalence of chronic pain and the preference for oral medications[1][3].
• China: China is expected to exhibit growth at a CAGR of nearly 5.3% in the global acetaminophen market. The increasing life expectancy and the resulting rise in non-communicable diseases are key drivers of this growth[3].
• India: India holds a substantial share of the South Asia market and is projected to display lucrative growth during the forecast period, driven by rising healthcare expenditures and easy access to affordable medications[3].

Pricing and Cost Analysis

The cost of butalbital-acetaminophen-caffeine varies based on the dosage form and quantity.

• Oral Tablets: A supply of 30 tablets (325 mg-50 mg-40 mg) can cost around $19.45 to $24.21, depending on the pharmacy and any discounts applied[2].
• Oral Capsules: For 100 capsules (325 mg-50 mg-40 mg), the cost can range from $153.91 to higher prices depending on the quantity and pharmacy[2].

Price Projections

Given the steady demand for pain management medications and the growing market size, prices are likely to remain stable or see a slight increase. Here are some key points to consider:

• Generic Availability: Since butalbital-acetaminophen-caffeine is available as a generic medication, prices are generally lower compared to brand-name versions. This trend is expected to continue, keeping prices competitive[1][2].
• Market Competition: The presence of multiple manufacturers, including major pharmaceutical companies like Pfizer, Sanofi, and GlaxoSmithKline, ensures competitive pricing. This competition is likely to maintain or reduce prices over time[3].
• Regulatory Factors: The drug's status as a schedule III controlled substance in some states but not federally in the U.S. may influence pricing due to regulatory compliance costs. However, this impact is expected to be minimal on the overall market[1].

Side Effects and Safety Considerations

Prolonged use of butalbital-acetaminophen-caffeine can lead to rebound headaches, and rare cases of Stevens–Johnson syndrome have been reported. These safety considerations may influence prescribing habits and patient compliance, potentially affecting market dynamics[1].

Mechanism of Action and Synergistic Effects

The combination of butalbital, acetaminophen, and caffeine targets multiple receptors, including A1R, A2aR, COX, and GABAA receptors, providing a broader spectrum of pain relief. This synergistic effect enhances the drug's efficacy and is a key factor in its market success[4].

Brand Names and Market Presence

Butalbital-acetaminophen-caffeine is available under brand names such as Fioricet and Esgic. These brands have a significant market presence and contribute to the overall demand for this medication[2].

Future Outlook

The future outlook for butalbital-acetaminophen-caffeine is positive, driven by the increasing need for effective pain management solutions. Here are some key points:

• Growing Demand: The rise in chronic illnesses and the need for opioid-tolerant pharmaceuticals will continue to drive demand for this medication[3].
• Oral Route Dominance: The oral route of administration, which accounts for about 92.4% of the market share, is expected to remain dominant due to its non-invasive, practical, and economical advantages[3].
• Regulatory Approval: The drug's regulatory approval and completion of clinical trials ensure its safety and efficacy, which will continue to support its market presence[4].

"The demand for acetaminophen is being driven by an increase in the number of people with chronic illnesses like cancer and chronic pulmonary obstructive disease (COPD)."[3]

Key Takeaways

• Market Growth: The global acetaminophen market, including butalbital-acetaminophen-caffeine, is expected to grow at a CAGR of 4.2% to 2033.
• Pricing Stability: Prices are likely to remain stable or see a slight increase due to generic availability and market competition.
• Synergistic Effects: The combination targets multiple receptors, enhancing its efficacy and market success.
• Regulatory Compliance: The drug's status as a controlled substance in some states may have minimal impact on pricing.
• Future Outlook: Growing demand for pain management solutions and the dominance of the oral route of administration will continue to support the market presence of this medication.

FAQs

What is the primary indication for butalbital-acetaminophen-caffeine?

The primary indication for butalbital-acetaminophen-caffeine is the treatment of tension headaches.

How does the combination of butalbital, acetaminophen, and caffeine work?

The combination targets multiple receptors, including A1R, A2aR, COX, and GABAA receptors, providing a synergistic effect in relieving pain. Acetaminophen offers analgesic and antipyretic properties, butalbital acts as a muscle relaxant and sedative, and caffeine enhances the overall pain-relieving effects.

What are the potential side effects of prolonged use of butalbital-acetaminophen-caffeine?

Prolonged use can lead to rebound headaches, and rare cases of Stevens–Johnson syndrome have been reported.

What is the current market size and growth projection for the acetaminophen market?

The global acetaminophen market was valued at USD 9.8 billion in 2022 and is projected to grow at a CAGR of 4.2% to reach USD 15.2 billion by 2033.

Are there any brand names for butalbital-acetaminophen-caffeine?

Yes, it is available under brand names such as Fioricet and Esgic.

Sources

1. Wikipedia: Butalbital/acetaminophen
2. Drugs.com: Acetaminophen/butalbital/caffeine Prices, Coupons, Copay Cards & Patient Assistance
3. Future Market Insights: Acetaminophen Market Size, Share, Trends & Outlook - 2033
4. Synapse: An In-depth Analysis of acetaminophen/butalbital/caffeine's R&D Progress
5. Drugs.com: Acetaminophen/butalbital/caffeine/codeine Prices, Coupons, Copay Cards & Patient Assistance

Last updated: 2024-12-30